title: [Intranasal administration of GnRH in the treatment of uterine myomatosis].
abstract: Nine patients in which an intranasal GnRH agonist analog (napharelin acetate) was administered with the purpose of decreasing the size of the myomas, were studied. In all a decrement in uterine and myoma size was observed. The FSH levels decreased since the first treated cycle, whereas LH and E2 levels initially increase, but finally decreased. The patients had menstrual bleeding between four and eight weeks after napharelin withdrawal. The mentioned results elicit the effectivity of GnRH agonist analog for leomyomata treatment.
authors.affiliation: Unidad de Investigación en Medicina Reproductivly, Hospital de Ginecología Obstetricia Luis Castelazo Ayala México, D.F.
authors.forename: C
authors.initials: C
authors.lastname: Morán
authors.forename: S
authors.initials: S
authors.lastname: Carranza-Lira
authors.forename: J C
authors.initials: JC
authors.lastname: Izquierdo
authors.forename: M
authors.initials: M
authors.lastname: Daza
authors.forename: R
authors.initials: R
authors.lastname: Bailón
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy*; D008595:Menorrhagia / Q000209:etiology; D017274:Nafarelin / Q000008:administration & dosage / Q000627:therapeutic use*; D009378:Neoplasms, Multiple Primary; D012074:Remission Induction; D014594:Uterine Neoplasms / Q000188:drug therapy*; D014599:Uterus / Q000187:drug effects
chemical_list: D017274:Nafarelin